-
Published 8/31/2022
Wexler DJ, Chang Y, Levy DE, Porneala B, McCarthy J, Rodriguez Romero A, Goldman V, Copeland PM, Steppel-Reznik J, Delahanty LM. Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trial. Obesity (Silver Spring). 2022 Oct; 30(10):1938-1950. PMID: 36046939.
-
Published 2/12/2019
Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, Henderson DC. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl). 2019 Jun; 236(6):1949-1957. PMID: 30747254.
-
Published 3/1/2018
Luo Y, Liu F, Natarajan R, Shukair N, Copeland P, Fan X. Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study. Int Clin Psychopharmacol. 2018 03; 33(2):88-91. PMID: 29084087.
-
Published 11/22/2017
Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, Henderson DC. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clin Schizophr Relat Psychoses. 2019; 12(4):168-176. PMID: 29164928.
-
Published 4/28/2015
Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015 May; 2(5):452-464. PMID: 26360288.